TY - JOUR
T1 - Diagnosis of myelodysplastic syndromes
T2 - the classic and the novel
AU - Oster, Howard S.
AU - van de Loosdrecht, Arjan A.
AU - Mittelman, Moshe
N1 - Publisher Copyright:
©2025 Ferrata Storti Foundation.
PY - 2025/2
Y1 - 2025/2
N2 - The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia with a tendency for leukemic transformation. The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for the diagnosis of MDS is still BM examination with the presence of uni-or multi-lineage dysplasia and blast percentage, together with exclusion of other reasons. Cytogenetics is also a part of the diagnostic process. Flow cytometry and genetics are helpful but are not always mandatory for the diagnosis of MDS. This review summarizes the current steps in the diagnostic approach for a patient suspected of having MDS. We also describe new concepts that use non-invasive diagnostic technologies, especially digital methods as well as peripheral blood genetics. The hope is that one day these will mature, be introduced into clinical practice, and perhaps in many cases even replace the invasive BM biopsy.
AB - The myelodysplastic syndromes (MDS) are a heterogenous group of clonal bone marrow (BM) stem cell myeloid neoplasms, characterized by BM dysplasia, macrocytic anemia or cytopenia with a tendency for leukemic transformation. The suspicion of MDS is raised by a typical but not specific clinical picture and routine laboratory findings, but the gold standard for the diagnosis of MDS is still BM examination with the presence of uni-or multi-lineage dysplasia and blast percentage, together with exclusion of other reasons. Cytogenetics is also a part of the diagnostic process. Flow cytometry and genetics are helpful but are not always mandatory for the diagnosis of MDS. This review summarizes the current steps in the diagnostic approach for a patient suspected of having MDS. We also describe new concepts that use non-invasive diagnostic technologies, especially digital methods as well as peripheral blood genetics. The hope is that one day these will mature, be introduced into clinical practice, and perhaps in many cases even replace the invasive BM biopsy.
UR - http://www.scopus.com/inward/record.url?scp=85216938268&partnerID=8YFLogxK
U2 - 10.3324/haematol.2023.284937
DO - 10.3324/haematol.2023.284937
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 39445407
AN - SCOPUS:85216938268
SN - 0390-6078
VL - 110
SP - 300
EP - 311
JO - Haematologica
JF - Haematologica
IS - 2
ER -